Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Arabinosyltransferase A inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: HIV Infections; Mycobacterium avium-intracellulare Infection; Tuberculosis; Tuberculosis, Pulmonary
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: INJECTION; ORAL; PERIODONTAL
STATUS: Approved
THERAPEUTIC AREA: DENTISTRY; OTHER
THERAPEUTIC INDICATION: Pelvic Inflammatory Disease; Tennis Elbow; Graves Ophthalmopathy; Macular Degeneration; Mucositis; Sexually Transmitted Diseases, Bacterial; Telangiectasia, Hereditary Hemorrhagic; Chlamydia Infections; Periodontitis; Rosacea; Acne Vulgaris
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ribonucleoside-diphosphate reductase RR1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Lung Neoplasms; Central Nervous System Neoplasms; Esophageal Neoplasms; Fibromatosis, Aggressive; Gliosarcoma; Head and Neck Neoplasms; Hemoglobin SC Disease; Leukemia, Myeloid, Acute; Lymphoma; Meningioma; Multiple Sclerosis; Muscular Atrophy, Spinal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stomach Neoplasms; Thalassemia; beta-Thalassemia; Carcinoma; Glioblastoma; HIV Infections; Hematologic Diseases; Hemochromatosis; Laryngeal Neoplasms; Leukemia; Leukemia, Promyelocytic, Acute; Mouth Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Paranasal Sinus Neoplasms; Pharyngeal Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Stroke; Thrombocythemia, Essential; Anemia, Sickle Cell; Carcinoma, Squamous Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acquired Immunodeficiency Syndrome; Meningitis; Mycobacterium avium-intracellulare Infection; Sarcoidosis; Mycobacterium Infections; Tuberculosis, Pulmonary; Uveitis, Anterior; Tuberculosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dysuria; Bacterial Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium-(potassium)-chloride cotransporter 2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Glaucoma; Urinary Bladder Neoplasms; Cardiovascular Diseases; Fibrosis; Heart Failure; Kidney Diseases; Nephrotic Syndrome; Pulmonary Edema
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thyroid hormone receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Down Syndrome; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: D2-like dopamine receptor inverse agonist
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Huntington Disease; Tobacco Use Disorder; Aggression; Amphetamine-Related Disorders; Mood Disorders; Alzheimer Disease; Anxiety; Bipolar Disorder; Delirium; Dementia; Depressive Disorder; Nausea; Postoperative Complications; Psychomotor Agitation; Conduct Disorder; Psychotic Disorders; Schizophrenia; Tics; Tourette Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Melanoma; Rhinoscleroma; Adenomatous Polyposis Coli; Amyloidosis; Amyloidosis, Familial; Aneurysm; Aortic Aneurysm, Abdominal; Blepharitis; Carcinoma, Non-Small-Cell Lung; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Cystic Fibrosis; Dermatitis, Atopic; Diabetic Foot; Diabetic Retinopathy; Dry Eye Syndromes; Eczema; Emphysema; Eye Burns; Graves Ophthalmopathy; Immunoglobulin Light-chain Amyloidosis; Lichen Planus, Oral; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mansonelliasis; Marfan Syndrome; Mycosis Fungoides; Myocardial Infarction; Neoplasms; Pain; Pancreatic Neoplasms; Parkinson Disease; Pelvic Inflammatory Disease; Plague; Reperfusion Injury; Seizures; Sezary Syndrome; Squamous Cell Carcinoma of Head and Neck; Alzheimer Disease; Arthritis, Reactive; Chlamydia Infections; Elephantiasis, Filarial; Hemorrhage; Idiopathic Pulmonary Fibrosis; Lyme Disease; Lymphoma; Osteoarthritis; Persian Gulf Syndrome; Pleural Effusion; Pulmonary Disease, Chronic Obstructive; Scrub Typhus; Severe Acute Respiratory Syndrome; Syphilis; Tuberculosis; Urethritis; Acne Vulgaris; Anthrax; Bacterial Infections; Brucellosis; Cholera; Gonorrhea; Infections; Malaria; Periodontitis; Pneumonia; Psittacosis; Rocky Mountain Spotted Fever; Rosacea; Spotted Fever Group Rickettsiosis; Tularemia; Typhus, Epidemic Louse-Borne
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sigma opioid receptor modulator
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thyroid hormone receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Myocardial Infarction; Myocardial Ischemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor alpha modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Infertility, Female; Hemorrhage; Infertility; Polycystic Ovary Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tubulin inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Helminthiasis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY; OTHER
THERAPEUTIC INDICATION: Psoriasis; Dermatitis, Atopic; Oral Submucous Fibrosis; Eye Diseases; Hemorrhoids; Lung Diseases, Obstructive; Nasal Obstruction; Skin Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Anxiety; Dementia; Depressive Disorder; Schizophrenia; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Mood Disorders; Attention Deficit Disorder with Hyperactivity; Cerebral Infarction; Cocaine-Related Disorders; Diabetes Mellitus, Type 2; Hepatitis C; Infections; Influenza, Human; Pain; Stroke; Hepatitis C, Chronic; Multiple Sclerosis; Psychotic Disorders; Schizophrenia; Severe Acute Respiratory Syndrome; Parkinson Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Penicillin-binding protein inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor agonist
ROUTE OF ADMINISTRATION: BUCCAL; INJECTION; NASAL; ORAL; SUBLINGUAL; TRANSMUCOSAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Pulpitis; Chronic Pain; Dyspnea; Low Back Pain; Lung Diseases, Interstitial; Neuralgia; Wounds and Injuries; Breakthrough Pain; Neoplasms; Pain
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Iron chelating agent
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cerebral Hemorrhage; Diabetes Mellitus, Type 1; Iron Overload
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Amidophosphoribosyltransferase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Inflammatory Bowel Diseases; Mucopolysaccharidoses; Myelodysplastic Syndromes; Urticaria; Anemia, Sickle Cell; Gout; Hepatitis, Autoimmune; Idiopathic Pulmonary Fibrosis; Infertility; Leukemia, Myeloid, Acute; Lung Diseases; Lung Diseases, Interstitial; Pemphigoid, Bullous; Pemphigus; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Hepatocellular; Cardiomyopathies; Churg-Strauss Syndrome; Colitis, Ulcerative; Crohn Disease; Eczema; Encephalomyelitis; Glomerulonephritis, IGA; Granulomatosis with Polyangiitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Microscopic Polyangiitis; Myasthenia Gravis; Neuromyelitis Optica; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Takayasu Arteritis; Thrombocytopenia; Vasculitis; Arthritis, Rheumatoid; Immune System Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cell membrane inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Hepatitis B, Chronic; Cocaine-Related Disorders; Epilepsy, Reflex; HIV Infections; Nausea; Anxiety; Dementia; Depressive Disorder; Schizophrenia; Bipolar Disorder; Epilepsies, Partial; Epilepsy; Glossopharyngeal Nerve Diseases; Seizures; Trigeminal Neuralgia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor agonist
ROUTE OF ADMINISTRATION: BUCCAL; SUBLINGUAL; TRANSDERMAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Opioid-Related Disorders; Respiratory Distress Syndrome; Brain Injuries; Breast Neoplasms; Bronchial Spasm; Delirium; Fractures, Bone; Hypospadias; Hypotension; Irritable Bowel Syndrome; Pulpitis; Scoliosis; Subarachnoid Hemorrhage; Abscess; Adenoma; Aortic Coarctation; Diabetic Neuropathies; Liver Diseases; Low Back Pain; Neoplasm Metastasis; Obesity; Obesity, Morbid; Osteoarthritis; Pancreatic Neoplasms; Renal Insufficiency, Chronic; Respiratory Insufficiency; Severe Acute Respiratory Syndrome; Sleep Apnea, Obstructive; Stomach Neoplasms; Acute Pain; Cancer Pain; Chronic Pain; Migraine Disorders; Neoplasms; Pain
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Endometrial Neoplasms; Hemorrhage
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Hepatocellular; Meningeal Carcinomatosis; Thalassemia; Acute Kidney Injury; Anemia, Sickle Cell; Breast Neoplasms; Cerebral Hemorrhage; Diabetic Foot; Ischemic Stroke; Subarachnoid Hemorrhage; Hemochromatosis; Severe Acute Respiratory Syndrome; beta-Thalassemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bacteremia; Gram-Positive Bacterial Infections; Bacterial Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Anandamide amidohydrolase inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS; ORAL; RECTAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Arrhythmias, Cardiac; Crohn Disease; Diabetes Mellitus, Type 2; Glycogen Storage Disease Type II; Hepatitis B, Chronic; Immune System Diseases; Intervertebral Disc Degeneration; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nervous System Diseases; Obesity, Morbid; Parkinson Disease; Pruritus; Purpura, Thrombocytopenic, Idiopathic; Anxiety; Arthritis, Rheumatoid; Borderline Personality Disorder; Brain Injuries; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cleft Palate; Diabetes Mellitus, Type 1; Digestive System Diseases; Fractures, Bone; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hypertension; Hypertrophy; Immunoglobulin G4-Related Disease; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Mucositis; Multiple Myeloma; Myelodysplastic Syndromes; Neck Pain; Neuralgia; Pre-Eclampsia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pulpitis; Renal Colic; Rotator Cuff Injuries; Sinusitis; Tension-Type Headache; Tonsillitis; Abdominal Pain; Chronic Pain; Delirium; Diabetic Neuropathies; Ductus Arteriosus, Patent; HIV Infections; Hemorrhage; Hypospadias; Infections; Kidney Calculi; Kidney Diseases; Low Back Pain; Lupus Erythematosus, Systemic; Lupus Nephritis; Malaria; Malaria, Falciparum; Meningitis, Bacterial; Multiple Sclerosis; Myopia; Nausea; Neoplasms; Obesity; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Paget Disease, Extramammary; Pemphigus; Postoperative Nausea and Vomiting; Respiratory Tract Infections; Scoliosis; Sepsis; Severe Acute Respiratory Syndrome; Streptococcal Infections; Vomiting; Wounds and Injuries; Acute Pain; Arthritis; Back Pain; Common Cold; Dysmenorrhea; Fever; Headache; Influenza, Human; Migraine Disorders; Muscle Cramp; Pain; Pharyngitis; Toothache
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glutamate [NMDA] receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Mood Disorders; Psychotic Disorders; Schizophrenia; Brain Injuries; Hepatitis C; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Infections; Influenza, Human; Intracranial Arteriosclerosis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Parkinsonian Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Bacterial Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor agonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Norepinephrine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Pain; Stomatitis; Alcoholism; Bipolar Disorder; Depression; Depressive Disorder; Dermatitis, Atopic; Sleep Initiation and Maintenance Disorders